Fe de errores de “Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD” (Arch Bronconeumol. (2017) 53 (128–49) (S0300289617300352) (10.1016/j.arbres.2017.02.001));Erratum to “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary” (Arch Bronconeumol. (2017) 53 (128–49) (S0300289617300352) (10.1016/j.arbres.2017.02.001));Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary;Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD

Archivos de Bronconeumologia

Volumn 53, Issue 3, 2017, Pages 128-149

  Vogelmeier, Claus F ^a   Criner, Gerard J ^h   Martínez, Fernando J ⁿ   Anzueto, Antonio ^c   Barnes, Peter J ^d   Bourbeau, Jean ^e   Celli, Bartolome R ^f   Chen, Rongchang ^g   Decramer, Marc ⁱ   Fabbri, Leonardo M ^j   Frith, Peter ^k   Halpin, David M G ^l   López Varela, M Victorina ^m   Nishimura, Masaharu ^o   Roche, Nicolás ^p   Rodríguez Roisin, Roberto ^b   Sin, Don D ^q   Singh, Dave ^r   Stockley, Robert ^s   Vestbo, Jørgen ^r   Wedzicha, Jadwiga A ^t   Agustí, Alvar ^b   more..

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BARCELONA   (Spain)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Primer Hospital Afiliado de la Universidad de Medicina de Guangzhou   (China)

^h TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Universidad de Lovaina   (United States)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k FLINDERS UNIVERSITY   (Australia)

^l ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^m UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

ⁿ WEILL CORNELL MEDICAL CENTER   (United States)

^o HOKKAIDO UNIVERSITY   (Japan)

^p Institut Cochin   (France)

^q UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^r UNIVERSITY OF MANCHESTER   (United Kingdom)

^s UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^t IMPERIAL COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Chronic obstructive pulmonary disease; COPD; COPD management; COPD prevention; diagnosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIOXIDANT; BRONCHODILATING AGENT; CORTICOSTEROID; DOMIODOL; OLODATEROL; PHOSPHODIESTERASE IV INHIBITOR; ALPHA 1 ANTITRYPSIN; AMFEBUTAMONE; ANTIINFLAMMATORY AGENT; ANTITUSSIVE AGENT; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ERYTHROMYCIN; GLUCOCORTICOID; INFLUENZA VACCINE; METHYLXANTHINE DERIVATIVE; MUCOLYTIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NORTRIPTYLINE; OXYGEN; PNEUMOCOCCUS VACCINE; VARENICLINE; VASODILATOR AGENT;

ARTICLE; ARTIFICIAL VENTILATION; BRONCHIECTASIS; BRONCHOSCOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG INDICATION; GASTROESOPHAGEAL REFLUX; GLOBAL STRATEGY FOR THE DIAGNOSIS MANAGEMENT PREVENTION OF CHRONIC OBSTRUCTIVE LUNG DISEASE 2017; HEALTH EDUCATION; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; HYPERTENSION; LUNG DISEASE; MEDICAL HISTORY; METABOLIC SYNDROME X; MONOTHERAPY; OSTEOPOROSIS; OXYGEN THERAPY; PRACTICE GUIDELINE; PROPHYLAXIS; PULMONARY REHABILITATION; SPIROMETRY; SYMPTOMATOLOGY; TREATMENT ASSESSMENT SCHEME; TREATMENT INDICATION; ANXIETY; ASSISTED VENTILATION; ASTHMA; BULLECTOMY; CHEST TIGHTNESS; COUGHING; DEPRESSION; DRUG DOSE ESCALATION; DYSPNEA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEART ARRHYTHMIA; HEART FAILURE; HOSPICE CARE; INDOOR AIR POLLUTION; INFLUENZA; LUNG CANCER; LUNG RESECTION; NICOTINE REPLACEMENT THERAPY; OCCUPATIONAL EXPOSURE; PALLIATIVE THERAPY; PATHOGENESIS; PATIENT CODING; PATIENT COUNSELING; PATIENT EDUCATION; PERIPHERAL VASCULAR DISEASE; PNEUMOCOCCAL INFECTION; RESPIRATORY AIRFLOW; RESPIRATORY TRACT INFECTION; RISK FACTOR; RISK REDUCTION; SLEEP DISORDERED BREATHING; SMOKING; SMOKING CESSATION; SPUTUM; TERMINAL CARE; TOBACCO DEPENDENCE; WHEEZING; MEDICAL EDUCATION; PATIENT CARE; RESPIRATORY TRACT DISEASE ASSESSMENT; SYMPTOM;

HUMANS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85014375458     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2017.06.001     Document Type: Erratum

References (345)

1. 1 Woodruff, P.G., Barr, R.G., Bleecker, E., et al. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med 374 (2016), 1811–1821.
2. 2 Regan, E.A., Lynch, D.A., Curran-Everett, D., et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA Intern Med 175 (2015), 1539–1549.
3. 3 Lamprecht, B., McBurnie, M.A., Vollmer, W.M., et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 139 (2011), 752–763.
4. 4 Thomsen, M., Nordestgaard, B.G., Vestbo, J., Lange, P., Characteristics and outcomes of chronic obstructive pulmonary disease in never smokers in Denmark: a prospective population study. The Lancet Respiratory medicine 1 (2013), 543–550.
5. 5 Barker, D.J., Godfrey, K.M., Fall, C., Osmond, C., Winter, P.D., Shaheen, S.O., Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 303 (1991), 671–675.
6. 6 Todisco, T., de Benedictis, F.M., Iannacci, L., et al. Mild prematurity and respiratory functions. Eur J Pediatr 152 (1993), 55–58.
7. 7 Stern, D.A., Morgan, W.J., Wright, A.L., Guerra, S., Martinez, F.D., Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study. Lancet 370 (2007), 758–764.
8. 8 Lawlor, D.A., Ebrahim, S., Davey Smith, G., Association of birth weight with adult lung function: findings from the British Women's Heart and Health Study and a meta-analysis. Thorax 60 (2005), 851–858.
9. 9 Kohansal, R., Martinez-Camblor, P., Agusti, A., Buist, A.S., Mannino, D.M., Soriano, J.B., The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 180 (2009), 3–10.
10. 10 Raad, D., Gaddam, S., Schunemann, H.J., et al. Effects of water-pipe smoking on lung function: a systematic review and meta-analysis. Chest 139 (2011), 764–774.
11. 11 She, J., Yang, P., Wang, Y., et al. Chinese water-pipe smoking and the risk of COPD. Chest 146 (2014), 924–931.
12. 12 Gunen, H., Tarraf, H., Nemati, A., Al Ghobain, M., Al Mutairi, S., Aoun Bacah, Z., Waterpipe tobacco smoking. Tuberk Toraks 64 (2016), 94–96.
13. 13 Tan, W.C., Lo, C., Jong, A., et al. Marijuana and chronic obstructive lung disease: a population-based study. CMAJ 180 (2009), 814–820.
14. 14 Yin, P., Jiang, C.Q., Cheng, K.K., et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet 370 (2007), 751–757.
15. 15 Tager, I.B., Ngo, L., Hanrahan, J.P., Maternal smoking during pregnancy. Effects on lung function during the first 18 months of life. Am J Respir Crit Care Med 152 (1995), 977–983.
16. 16 Paulin, L.M., Diette, G.B., Blanc, P.D., et al. Occupational exposures are associated with worse morbidity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191 (2015), 557–565.
17. 17 Eisner, M.D., Anthonisen, N., Coultas, D., et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182 (2010), 693–718.
18. 18 Orozco-Levi, M., Garcia-Aymerich, J., Villar, J., Ramirez-Sarmiento, A., Anto, J.M., Gea, J., Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J 27 (2006), 542–546.
19. 19 Gan, W.Q., FitzGerald, J.M., Carlsten, C., Sadatsafavi, M., Brauer, M., Associations of ambient air pollution with chronic obstructive pulmonary disease hospitalization and mortality. Am J Respir Crit Care Med 187 (2013), 721–727.
20. 20 Ezzati, M., Indoor air pollution and health in developing countries. Lancet 366 (2005), 104–106.
21. 21 Zhou, Y., Zou, Y., Li, X., et al. Lung function and incidence of chronic obstructive pulmonary disease after improved cooking fuels and kitchen ventilation: a 9-year prospective cohort study. PLoS Med, 11, 2014, e1001621.
22. 22 Silva, G.E., Sherrill, D.L., Guerra, S., Barbee, R.A., Asthma as a risk factor for COPD in a longitudinal study. Chest 126 (2004), 59–65.
23. 23 Rijcken, B., Schouten, J.P., Weiss, S.T., Speizer, F.E., van der Lende, R., The relationship of nonspecific bronchial responsiveness to respiratory symptoms in a random population sample. Am Rev Respir Dis 136 (1987), 62–68.
24. 24 Hospers, J.J., Postma, D.S., Rijcken, B., Weiss, S.T., Schouten, J.P., Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 356 (2000), 1313–1317.
25. 25 Tashkin, D.P., Altose, M.D., Connett, J.E., Kanner, R.E., Lee, W.W., Wise, R.A., Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 153:6 Pt 1 (1996), 1802–1811.
26. 26 de Marco, R., Accordini, S., Marcon, A., et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 183 (2011), 891–897.
27. 27 Drummond, M.B., Kirk, G.D., HIV-associated obstructive lung diseases: insights and implications for the clinician. The Lancet Respiratory medicine 2 (2014), 583–592.
28. 28 Menezes, A.M., Hallal, P.C., Perez-Padilla, R., et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 30 (2007), 1180–1185.
29. 29 Jordan, T.S., Spencer, E.M., Davies, P., Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology 15 (2010), 623–628.
30. 30 Byrne, A.L., Marais, B.J., Mitnick, C.D., Lecca, L., Marks, G.B., Tuberculosis and chronic respiratory disease: a systematic review. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 32 (2015), 138–146.
31. 31 Buist, A.S., McBurnie, M.A., Vollmer, W.M., et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370 (2007), 741–750.
32. 32 Miravitlles, M., Worth, H., Soler Cataluna, J.J., et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res, 15, 2014, 122.
33. 33 Elliott, M.W., Adams, L., Cockcroft, A., MacRae, K.D., Murphy, K., Guz, A., The language of breathlessness. Use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis 144 (1991), 826–832.
34. 34 Medical Research Council Committee on the Aetiology of Chronic Bronchitis, Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet 1 (1965), 775–779.
35. 35 von Haehling, S., Anker, S.D., Cachexia as a major underestimated and unmet medical need: facts and numbers. Journal of cachexia, sarcopenia and muscle 1 (2010), 1–5.
36. 36 Schols, A.M., Soeters, P.B., Dingemans, A.M., Mostert, R., Frantzen, P.J., Wouters, E.F., Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 147 (1993), 1151–1156.
37. 37 Holleman, D.R. Jr., Simel, D.L., Does the clinical examination predict airflow limitation?. Jama 273 (1995), 313–319.
38. 38 Kesten, S., Chapman, K.R., Physician perceptions and management of COPD. Chest 104 (1993), 254–258.
39. 39 van Dijk, W., Tan, W., Li, P., et al. Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort. Annals of family medicine 13 (2015), 41–48.
40. 40 Guder, G., Brenner, S., Angermann, C.E., et al. GOLD or lower limit of normal definition?. A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study”. Respir Res, 13, 2012, 13.
41. 41 Vaz Fragoso, C.A., McAvay, G., Van Ness, P.H., et al. Phenotype of normal spirometry in an aging population. Am J Respir Crit Care Med 192 (2015), 817–825.
42. 42 Vaz Fragoso, C.A., McAvay, G., Van Ness, P.H., et al. Phenotype of Spirometric Impairment in an Aging Population. Am J Respir Crit Care Med 193 (2016), 727–735.
43. 43 Albert, P., Agusti, A., Edwards, L., et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 67 (2012), 701–708.
44. 44 Hansen, J.E., Porszasz, J., Counterpoint:, Is an increase in FEV(1) and/or FVC>/= 12% of control and >/= 200 mL the best way to assess positive bronchodilator response?. No. Chest 146 (2014), 538–541.
45. 45 Hill, K., Goldstein, R.S., Guyatt, G.H., et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ 182 (2010), 673–678.
46. 46 Lopez Varela, M.V., Montes de Oca, M., Rey, A., et al. Development of a simple screening tool for opportunistic COPD case finding in primary care in Latin America: The PUMA study. Respirology 21 (2016), 1227–1234.
47. 47 Dirven, J.A., Tange, H.J., Muris, J.W., van Haaren, K.M., Vink, G., van Schayck, O.C., Early detection of COPD in general practice: implementation, workload and socioeconomic status. A mixed methods observational study. Prim Care Respir J 22 (2013), 338–343.
48. 48 Fletcher, C.M., Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ, 2, 1960, 1662.
49. 49 Bestall, J.C., Paul, E.A., Garrod, R., Garnham, R., Jones, P.W., Wedzicha, J.A., Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54 (1999), 581–586.
50. 50 Sundh, J., Janson, C., Lisspers, K., Stallberg, B., Montgomery, S., The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. Prim Care Respir J 21 (2012), 295–301.
51. 51 Nishimura, K., Izumi, T., Tsukino, M., Oga, T., Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121 (2002), 1434–1440.
52. 52 Jones, P.W., Health status measurement in chronic obstructive pulmonary disease. Thorax 56 (2001), 880–887.
53. 53 Guyatt, G.H., Berman, L.B., Townsend, M., Pugsley, S.O., Chambers, L.W., A measure of quality of life for clinical trials in chronic lung disease. Thorax 42 (1987), 773–778.
54. 54 Jones, P.W., Quirk, F.H., Baveystock, C.M., Littlejohns, P., A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 145 (1992), 1321–1327.
55. 55 Agusti, A., Calverley, P.M., Celli, B., et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res, 11, 2010, 122.
56. 56 Nishimura, K., Mitsuma, S., Kobayashi, A., et al. COPD and disease-specific health status in a working population. Respir Res, 14, 2013, 61.
57. 57 Miravitlles, M., Soriano, J., Garcia-Rio, F., et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 64 (2009), 863–868.
58. 58 Jones, P.W., Tabberer, M., Chen, W.H., Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med, 11, 2011, 42.
59. 59 Hurst, J.R., Vestbo, J., Anzueto, A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363 (2010), 1128–1138.
60. 60 Soler-Cataluna, J.J., Martinez-Garcia, M.A., Roman Sanchez, P., Salcedo, E., Navarro, M., Ochando, R., Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 (2005), 925–931.
61. 61 Pascoe, S., Locantore, N., Dransfield, M., Barnes, N.C., Pavord, I.D., Blood eosiophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parrallel randomised controlled trials. Lancet Respiratory Medicine 3 (2015), 435–442.
62. 62 Siddiqui, S.H., Guasconi, A., Vestbo, J., et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 192 (2015), 523–525.
63. 63 Soriano, J.B., Visick, G.T., Muellerova, H., Payvandi, N., Hansell, A.L., Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 128 (2005), 2099–2107.
64. 64 National Institute for Health and Care Excellence Multimorbidity: clinical assessment and management, in press. 2016. https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0704/documents (accessed 1 August 2016).
65. 65 Vanfleteren, L.E., Spruit, M.A., Groenen, M., et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187 (2013), 728–735.
66. 66 Soriano, J.B., Lamprecht, B., Ramirez, A.S., et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. The Lancet Respiratory medicine 3 (2015), 443–450.
67. 67 Goossens, L.M., Leimer, I., Metzdorf, N., Becker, K., Rutten-van Molken, M.P., Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med, 14, 2014, 163.
68. 68 Kim, J., Yoon, H.I., Oh, Y.M., et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 10 (2015), 1819–1827.
69. 69 Han, M.K., Muellerova, H., Curran-Everett, D., et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. The Lancet Respiratory medicine 1 (2013), 43–50.
70. 70 WHO meeting participants, Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 75 (1997), 397–415.
71. 71 Celli, B.R., Cote, C.G., Marin, J.M., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 (2004), 1005–1012.
72. 72 Jones, R.C., Donaldson, G.C., Chavannes, N.H., et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 180 (2009), 1189–1195.
73. 73 Puhan, M.A., Garcia-Aymerich, J., Frey, M., et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 374 (2009), 704–711.
74. 74 van Eerd, E.A., van der Meer, R.M., van Schayck, O.C., Kotz, D., Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2016, CD010744.
75. 75 The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives, A clinical practice guideline for treating tobacco use and dependence. JAMA 28 (2000), 3244–3254.
76. 76 van der Meer, R.M., Wagena, E.J., Ostelo, R.W., Jacobs, J.E., van Schayck, C.P., Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2003, CD002999.
77. 77 A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. American journal of preventive medicine 35 (2008), 158–176.
78. 78 McNeill, A., Brose, L.S., Calder, R., Hitchman, S.C., E-cigarettes: an evidence update. A report commissioned by Public Health England.: Public Health England. 2015.
79. 79 McRobbie, H., Bullen, C., Hartmann-Boyce, J., Hajek, P., Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev, 12, 2014, CD010216.
80. 80 Kalkhoran, S., Glantz, S.A., E-cigarettes and smoking cessation - Authors’ reply. The Lancet Respiratory medicine 4 (2016), e26–e27.
81. 81 Malas, M., van der Tempel, J., Schwartz, R., et al. Electronic Cigarettes for Smoking Cessation: A Systematic Review. Nicotine Tob Res 18 (2016), 1926–1936.
82. 82 Beard, E., West, R., Michie, S., Brown, J., Association between electronic cigarette use and changes in quit attempts, success of quit attempts, use of smoking cessation pharmacotherapy, and use of stop smoking services in England: time series analysis of population trends. Bmj, 354, 2016, i4645.
83. 83 Tashkin, D.P., Rennard, S., Hays, J.T., Ma, W., Lawrence, D., Lee, T.C., Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 139 (2011), 591–599.
84. 84 Tashkin, D., Kanner, R., Bailey, W., et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357 (2001), 1571–1575.
85. 85 Cahill, K., Stevens, S., Perera, R., Lancaster, T., Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev, 5, 2013, CD009329.
86. 86 The Tobacco Use and Dependence Clinical Practice Guideline Panel, A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. JAMA 283 (2000), 3244–3254.
87. 87 The Tobacco Use and Dependence Clinical Practice Guideline Panel, A clinical practice guideline for treating tobacco use and dependence. JAMA 28 (2000), 3244–3254.
88. 88 Glynn, T., Manley, M., How to help your patients stop smoking. U.S. Department of Health and Human Services PHS, National Institutes of Health, National Cancer Institute, (eds.) A National Cancer Institute manual for physicians., 1990.
89. 89 Stead, L.F., Buitrago, D., Preciado, N., Sanchez, G., Hartmann-Boyce, J., Lancaster, T., Physician advice for smoking cessation. Cochrane Database Syst Rev, 5, 2013, CD000165.
90. 90 Stead, L.F., Koilpillai, P., Fanshawe, T.R., Lancaster, T., Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev, 3, 2016, CD008286.
91. 91 Wongsurakiat, P., Maranetra, K.N., Wasi, C., Kositanont, U., Dejsomritrutai, W., Charoenratanakul, S., Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 125 (2004), 2011–2020.
92. 92 Poole, P.J., Chacko, E., Wood-Baker, R.W., Cates, C.J., Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2006, CD002733.
93. 93 Wongsurakiat, P., Lertakyamanee, J., Maranetra, K.N., Jongriratanakul, S., Sangkaew, S., Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. J Med Assoc Thai 86 (2003), 497–508.
94. 94 Nichol, K.L., Margolis, K.L., Wuorenma, J., Von Sternberg, T., The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 331 (1994), 778–784.
95. 95 Fiore, A.E., Shay, D.K., Broder, K., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 58:RR-8 (2009), 1–52.
96. 96 Huang, C.L., Nguyen, P.A., Kuo, P.L., Iqbal, U., Hsu, Y.H., Jian, W.S., Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly. Comput Methods Programs Biomed 111 (2013), 507–511.
97. 97 Edwards, K.M., Dupont, W.D., Westrich, M.K., Plummer, W.D. Jr., Palmer, P.S., Wright, P.F., A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169 (1994), 68–76.
98. 98 Hak, E., van Essen, G.A., Buskens, E., Stalman, W., de Melker, R.A., Is immunising all patients with chronic lung disease in the community against influenza cost effective?. Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. J Epidemiol Community Health 52 (1998), 120–125.
99. 99 Burge, P.S., Calverley, P.M., Jones, P.W., Spencer, S., Anderson, J.A., Maslen, T.K., Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000), 1297–1303.
100. 100 Anthonisen, N.R., Connett, J.E., Kiley, J.P., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 (1994), 1497–1505.
101. 101 Pauwels, R.A., Lofdahl, C.G., Laitinen, L.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340 (1999), 1948–1953.
102. 102 Vestbo, J., Sorensen, T., Lange, P., Brix, A., Torre, P., Viskum, K., Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353 (1999), 1819–1823.
103. 103 Tashkin, D.P., Celli, B., Senn, S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 (2008), 1543–1554.
104. 104 O'Donnell, D.E., Fluge, T., Gerken, F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004), 832–840.
105. 105 O'Donnell, D.E., Sciurba, F., Celli, B., et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 130 (2006), 647–656.
106. 106 Appleton, S., Jones, T., Poole, P., et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2006, Cd006101.
107. 107 Karner, C., Chong, J., Poole, P., Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 7, 2014, CD009285.
108. 108 Melani, A.S., Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol 8 (2015), 479–501.
109. 109 Kesten, S., Casaburi, R., Kukafka, D., Cooper, C.B., Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 3 (2008), 127–136.
110. 110 Casaburi, R., Kukafka, D., Cooper, C.B., Witek, T.J. Jr., Kesten, S., Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127 (2005), 809–817.
111. 111 Vogelmeier, C., Hederer, B., Glaab, T., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364 (2011), 1093–1103.
112. 112 Decramer, M.L., Chapman, K.R., Dahl, R., et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. The Lancet Respiratory medicine 1 (2013), 524–533.
113. 113 Anthonisen, N.R., Connett, J.E., Enright, P.L., Manfreda, J., Lung Health Study Research, G., Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 166 (2002), 333–339.
114. 114 Michele, T.M., Pinheiro, S., Iyasu, S., The safety of tiotropium–the FDA's conclusions. N Engl J Med 363 (2010), 1097–1099.
115. 115 Wise, R.A., Anzueto, A., Cotton, D., et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 369 (2013), 1491–1501.
116. 116 Ram, F.S., Jones, P.W., Castro, A.A., et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2002, CD003902.
117. 117 ZuWallack, R.L., Mahler, D.A., Reilly, D., et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 119 (2001), 1661–1670.
118. 118 Zacarias, E.C., Castro, A.A., Cendon, S., Effect of theophylline associated with short-acting or long-acting inhaled beta2-agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. J Bras Pneumol 33 (2007), 152–160.
119. 119 Cosio, B.G., Shafiek, H., Iglesias, A., et al. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. Chest 150 (2016), 123–130.
120. 120 Zhou, Y., Wang, X., Zeng, X., et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 11 (2006), 603–610.
121. 121 McKay, S.E., Howie, C.A., Thomson, A.H., Whiting, B., Addis, G.J., Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 48 (1993), 227–232.
122. 122 Cazzola, M., Molimard, M., The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 23 (2010), 257–267.
123. 123 van der Molen, T., Cazzola, M., Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 21 (2012), 101–108.
124. 124 Mahler, D.A., Decramer, M., D'Urzo, A., et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 43 (2014), 1599–1609.
125. 125 Singh, D., Ferguson, G.T., Bolitschek, J., et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med 109 (2015), 1312–1319.
126. 126 Bateman, E.D., Chapman, K.R., Singh, D., et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res, 16, 2015, 92.
127. 127 Mahler, D.A., Kerwin, E., Ayers, T., et al. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 192 (2015), 1068–1079.
128. 128 Wedzicha, J.A., Decramer, M., Ficker, J.H., et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. The Lancet Respiratory medicine 1 (2013), 199–209.
129. 129 Wedzicha, J.A., Banerji, D., Chapman, K.R., et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 374 (2016), 2222–2234.
130. 130 Nannini, L.J., Lasserson, T.J., Poole, P., Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 9, 2012, CD006829.
131. 131 Nannini, L.J., Poole, P., Milan, S.J., Kesterton, A., Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 8, 2013, CD006826.
132. 132 Calverley, P.M., Anderson, J.A., Celli, B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007), 775–789.
133. 133 Vestbo, J., Anderson, J.A., Brook, R.D., et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 387:10030 (2016), 1817–1826.
134. 134 Yang, I.A., Clarke, M.S., Sim, E.H., Fong, K.M., Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 7, 2012, CD002991.
135. 135 Crim, C., Dransfield, M.T., Bourbeau, J., et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Annals of the American Thoracic Society 12 (2015), 27–34.
136. 136 Johnell, O., Pauwels, R., Lofdahl, C.G., et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 19 (2002), 1058–1063.
137. 137 Ferguson, G.T., Calverley, P.M., Anderson, J.A., et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 136 (2009), 1456–1465.
138. 138 Dransfield, M.T., Bourbeau, J., Jones, P.W., et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. The Lancet Respiratory medicine 1 (2013), 210–223.
139. 139 Loke, Y.K., Cavallazzi, R., Singh, S., Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66 (2011), 699–708.
140. 140 Suissa, S., Kezouh, A., Ernst, P., Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 123 (2010), 1001–1006.
141. 141 Wang, J.J., Rochtchina, E., Tan, A.G., Cumming, R.G., Leeder, S.R., Mitchell, P., Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology 116 (2009), 652–657.
142. 142 Andrejak, C., Nielsen, R., Thomsen, V.O., Duhaut, P., Sorensen, H.T., Thomsen, R.W., Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 68 (2013), 256–262.
143. 143 Dong, Y.H., Chang, C.H., Lin Wu, F.L., et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. Chest 145 (2014), 1286–1297.
144. 144 Lee, C.H., Kim, K., Hyun, M.K., Jang, E.J., Lee, N.R., Yim, J.J., Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 68 (2013), 1105–1113.
145. 145 Nadeem, N.J., Taylor, S.J., Eldridge, S.M., Withdrawal of inhaled corticosteroids in individuals with COPD–a systematic review and comment on trial methodology. Respir Res, 12, 2011, 107.
146. 146 van der Valk, P., Monninkhof, E., van der Palen, J., Zielhuis, G., van Herwaarden, C., Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 166 (2002), 1358–1363.
147. 147 Wouters, E.F., Postma, D.S., Fokkens, B., et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 60 (2005), 480–487.
148. 148 Kunz, L.I., Postma, D.S., Klooster, K., et al. Relapse in FEV1 Decline After Steroid Withdrawal in COPD. Chest 148 (2015), 389–396.
149. 149 Magnussen, H., Disse, B., Rodriguez-Roisin, R., et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371 (2014), 1285–1294.
150. 150 Welte, T., Miravitlles, M., Hernandez, P., et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 180 (2009), 741–750.
151. 151 Singh, D., Brooks, J., Hagan, G., Cahn, A., O'Connor, B.J., Superiority of «triple» therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63 (2008), 592–598.
152. 152 Jung, K.S., Park, H.Y., Park, S.Y., et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 106 (2012), 382–389.
153. 153 Hanania, N.A., Crater, G.D., Morris, A.N., Emmett, A.H., O'Dell, D.M., Niewoehner, D.E., Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 106 (2012), 91–101.
154. 154 Frith, P.A., Thompson, P.J., Ratnavadivel, R., et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax 70 (2015), 519–527.
155. 155 Siler, T.M., Kerwin, E., Singletary, K., Brooks, J., Church, A., Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized. Double-Blind Studies. COPD 13 (2016), 1–10.
156. 156 Singh, D., Papi, A., Corradi, M., et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388:10048 (2016), 963–973.
157. 157 Aaron, S.D., Vandemheen, K.L., Fergusson, D., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146 (2007), 545–555.
158. 158 Calverley, P.M., Rabe, K.F., Goehring, U.M., et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374 (2009), 685–694.
159. 159 Chong, J., Leung, B., Poole, P., Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 11, 2013, CD002309.
160. 160 Seemungal, T.A., Wilkinson, T.M., Hurst, J.R., Perera, W.R., Sapsford, R.J., Wedzicha, J.A., Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 178 (2008), 1139–1147.
161. 161 Uzun, S., Djamin, R.S., Kluytmans, J.A., et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. The Lancet Respiratory medicine 2 (2014), 361–368.
162. 162 Albert, R.K., Connett, J., Bailey, W.C., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365 (2011), 689–698.
163. 163 Sethi, S., Jones, P.W., Theron, M.S., et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res, 11, 2010, 10.
164. 164 Cazzola, M., Calzetta, L., Page, C., et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev 24 (2015), 451–461.
165. 165 Poole, P., Chong, J., Cates, C.J., Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2015, CD001287.
166. 166 Collet, J.P., Shapiro, P., Ernst, P., Renzi, T., Ducruet, T., Robinson, A., Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am J Respir Crit Care Med 156 (1997), 1719–1724.
167. 167 Li, J., Zheng, J.P., Yuan, J.P., Zeng, G.Q., Zhong, N.S., Lin, C.Y., Protective effect of a bacterial extract against acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease. Chin Med J (Engl) 117 (2004), 828–834.
168. 168 Lee, J.H., Kim, H.J., Kim, Y.H., The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis. Lung 193 (2015), 477–486.
169. 169 Rennard, S.I., Fogarty, C., Kelsen, S., et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007), 926–934.
170. 170 Criner, G.J., Connett, J.E., Aaron, S.D., et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 370 (2014), 2201–2210.
171. 171 Ingebrigtsen, T.S., Marott, J.L., Nordestgaard, B.G., Lange, P., Hallas, J., Vestbo, J., Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax 70 (2015), 33–40.
172. 172 Lehouck, A., Mathieu, C., Carremans, C., et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 156 (2012), 105–114.
173. 173 Melani, A.S., Bonavia, M., Cilenti, V., et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 105 (2011), 930–938.
174. 174 Rootmensen, G.N., van Keimpema, A.R., Jansen, H.M., de Haan, R.J., Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv 23 (2010), 323–328.
175. 175 Dantic, D.E., A critical review of the effectiveness of «teach-back» technique in teaching COPD patients self-management using respiratory inhalers. Health Educ J 73 (2014), 41–50.
176. 176 Chapman, K.R., Stockley, R.A., Dawkins, C., Wilkes, M.M., Navickis, R.J., Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. Copd 6 (2009), 177–184.
177. 177 Chapman, K.R., Burdon, J.G., Piitulainen, E., et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 386 (2015), 360–368.
178. 178 Dirksen, A., Dijkman, J.H., Madsen, F., et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160:5 Pt 1 (1999), 1468–1472.
179. 179 Dirksen, A., Piitulainen, E., Parr, D.G., et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 33 (2009), 1345–1353.
180. 180 Schildmann, E.K., Remi, C., Bausewein, C., Levodropropizine in the management of cough associated with cancer or nonmalignant chronic disease–a systematic review. J Pain Palliat Care Pharmacother 25 (2011), 209–218.
181. 181 Barbera, J.A., Roger, N., Roca, J., Rovira, I., Higenbottam, T.W., Rodriguez-Roisin, R., Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 347 (1996), 436–440.
182. 182 Blanco, I., Santos, S., Gea, J., et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 42 (2013), 982–992.
183. 183 Goudie, A.R., Lipworth, B.J., Hopkinson, P.J., Wei, L., Struthers, A.D., Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. The Lancet Respiratory medicine 2 (2014), 293–300.
184. 184 Spruit, M.A., Singh, S.J., Garvey, C., et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 188 (2013), e13–e64.
185. 185 Puhan, M.A., Gimeno-Santos, E., Scharplatz, M., Troosters, T., Walters, E.H., Steurer, J., Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2011, CD005305.
186. 186 Greening, N.J., Williams, J.E., Hussain, S.F., et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ, 349, 2014, g4315.
187. 187 Vogiatzis, I., Rochester, C.L., Spruit, M.A., Troosters, T., Clini, E.M., American Thoracic Society/European Respiratory Society Task Force on Policy in Pulmonary Rehabilitation. Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement. Eur Respir J 47 (2016), 1336–1341.
188. 188 Zwerink, M., Brusse-Keizer, M., van der Valk, P.D., et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3, 2014, CD002990.
189. 189 Fan, V.S., Gaziano, J.M., Lew, R., et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med 156 (2012), 673–683.
190. 190 Peytremann-Bridevaux, I., Taffe, P., Burnand, B., Bridevaux, P.O., Puhan, M.A., Mortality of patients with COPD participating in chronic disease management programmes: a happy end?. Thorax 69 (2014), 865–866.
191. 191 Kruis, A.L., Smidt, N., Assendelft, W.J., et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 10, 2013, CD009437.
192. 192 Kruis, A.L., Boland, M.R., Assendelft, W.J., et al. Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. BMJ, 349, 2014, g5392.
193. 193 Cartwright, M., Hirani, S.P., Rixon, L., et al. Effect of telehealth on quality of life and psychological outcomes over 12 months (Whole Systems Demonstrator telehealth questionnaire study): nested study of patient reported outcomes in a pragmatic, cluster randomised controlled trial. BMJ, 346, 2013, f653.
194. 194 American Academy of Hospice and Palliative Medicine Center to Advance Palliative Care Hospice and Palliative Nurses Association Last Acts Partnership National Hospice and Palliative Care Organization. National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary. Journal of palliative medicine 7 (2004), 611–627.
195. 195 Halpin, D.M.G., Seamark, D.A., Seamark, C.J., Palliative and end-of-life care for patients with respiratory diseases. Eur Respir Monograph 43 (2009), 327–353.
196. 196 Weber, C., Stirnemann, J., Herrmann, F.R., Pautex, S., Janssens, J.P., Can early introduction of specialized palliative care limit intensive care, emergency and hospital admissions in patients with severe and very severe COPD?. a randomized study. BMC Palliat Care, 13, 2014, 47.
197. 197 Ek, K., Andershed, B., Sahlberg-Blom, E., Ternestedt, B.M., The unpredictable death”-The last year of life for patients with advanced COPD: Relatives’ stories. Palliat Support Care 13 (2015), 1213–1222.
198. 198 Cranston, J.M., Crockett, A.J., Moss, J.R., Alpers, J.H., Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2005, CD001744.
199. 199 Long-term Oxygen Treatment Trial Research Group, A randomized trial of long-term oxygen for COPD with moderate desaturation. NEJM, 375, 2016, 1617.
200. 200 Galli, J.A., Krahnke, J.S., James Mamary, A., Shenoy, K., Zhao, H., Criner, G.J., Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. Respir Med 108 (2014), 722–728.
201. 201 Coughlin, S., Liang, W.E., Parthasarathy, S., Retrospective Assessment of Home Ventilation to Reduce Rehospitalization in Chronic Obstructive Pulmonary Disease. Journal of clinical sleep medicine: JCSM: official publication of the American Academy of Sleep Medicine 11 (2015), 663–670.
202. 202 Clini, E., Sturani, C., Rossi, A., et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 20 (2002), 529–538.
203. 203 Kohnlein, T., Windisch, W., Kohler, D., et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. The Lancet Respiratory medicine 2 (2014), 698–705.
204. 204 Struik, F.M., Sprooten, R.T., Kerstjens, H.A., et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax 69 (2014), 826–834.
205. 205 Casanova, C., Celli, B.R., Tost, L., et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 118 (2000), 1582–1590.
206. 206 Marin, J.M., Soriano, J.B., Carrizo, S.J., Boldova, A., Celli, B.R., Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 182 (2010), 325–331.
207. 207 Fishman, A., Martinez, F., Naunheim, K., et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348 (2003), 2059–2073.
208. 208 National Emphysema Treatment Trial Research Group, Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 345 (2001), 1075–1083.
209. 209 Marchetti, N., Criner, G.J., Surgical Approaches to Treating Emphysema: Lung Volume Reduction Surgery, Bullectomy, and Lung Transplantation. Semin Respir Crit Care Med 36 (2015), 592–608.
210. 210 Christie, J.D., Edwards, L.B., Kucheryavaya, A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 31 (2012), 1073–1086.
211. 211 Stavem, K., Bjortuft, O., Borgan, O., Geiran, O., Boe, J., Lung transplantation in patients with chronic obstructive pulmonary disease in a national cohort is without obvious survival benefit. J Heart Lung Transplant 25 (2006), 75–84.
212. 212 Thabut, G., Christie, J.D., Ravaud, P., et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet 371 (2008), 744–751.
213. 213 Criner, G.J., Cordova, F., Sternberg, A.L., Martinez, F.J., The National Emphysema Treatment Trial (NETT) Part II: Lessons learned about lung volume reduction surgery. Am J Respir Crit Care Med 184 (2011), 881–893.
214. 214 Shah, P.L., Slebos, D.J., Cardoso, P.F., et al. Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial. Lancet 378 (2011), 997–1005.
215. 215 Come, C.E., Kramer, M.R., Dransfield, M.T., et al. A randomised trial of lung sealant versus medical therapy for advanced emphysema. Eur Respir J 46 (2015), 651–662.
216. 216 Sciurba, F.C., Ernst, A., Herth, F.J., et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 363 (2010), 1233–1244.
217. 217 Davey, C., Zoumot, Z., Jordan, S., et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi trial): study design and rationale. Thorax 70 (2015), 288–290.
218. 218 Klooster, K., ten Hacken, N.H., Hartman, J.E., Kerstjens, H.A., van Rikxoort, E.M., Slebos, D.J., Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med 373 (2015), 2325–2335.
219. 219 Deslee, G., Mal, H., Dutau, H., et al. Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. JAMA 315 (2016), 175–184.
220. 220 Sciurba, F.C., Criner, G.J., Strange, C., et al. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. JAMA 315 (2016), 2178–2189.
221. 221 Barr, R.G., Bourbeau, J., Camargo, C.A., Ram, F.S., Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2005, CD002876.
222. 222 Karner, C., Cates, C.J., Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2012, Cd008989.
223. 223 Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Molken, M.P., Beeh, K.M., et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364 (2011), 1093–1103.
224. 224 Martinez, F.J., Calverley, P.M., Goehring, U.M., Brose, M., Fabbri, L.M., Rabe, K.F., Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385 (2015), 857–866.
225. 225 Martinez, F.J., Rabe, K.F., Sethi, S., Pizzichini, E., McIvor, A., Anzueto, A., et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med 194 (2016), 559–567.
226. 226 Vogiatzis, I., Rochester, C.L., Spruit, M.A., Troosters, T., Clini, E.M., American Thoracic Society/European Respiratory Society Task Force on Policy in Pulmonary R. Increasing implementation and delivery of pulmonary rehabilitation: key messages from the new ATS/ERS policy statement. Eur Respir J 47 (2016), 1336–1341.
227. 227 Garvey, C., Bayles, M.P., Hamm, L.F., Hill, K., Holland, A., Limberg, T.M., et al. Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary Disease: Review of Selected Guidelines: An official statement from the American Association of Cardiovascular and Pulmonary Rehabilitation. J Cardiopulm Rehabil Prev 36 (2016), 75–83.
228. 228 Ortega, F., Toral, J., Cejudo, P., Villagomez, R., Sanchez, H., Castillo, J., et al. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166 (2002), 669–674.
229. 229 Bernard, S., Whittom, F., Leblanc, P., Jobin, J., Belleau, R., Berube, C., et al. Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 159 (1999), 896–901.
230. 230 Velloso, M., do Nascimento, N.H., Gazzotti, M.R., Jardim, J.R., Evaluation of effects of shoulder girdle training on strength and performance of activities of daily living in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 8 (2013), 187–192.
231. 231 Au, D.H., Udris, E.M., Engelberg, R.A., Diehr, P.H., Bryson, C.L., Reinke, L.F., et al. A randomized trial to improve communication about end-of-life care among patients with COPD. Chest 141 (2012), 726–735.
232. 232 Tomczyk, S., Bennett, N.M., Stoecker, C., Gierke, R., Moore, M.R., Whitney, C.G., et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 63 (2014), 822–825.
233. 233 Struik, F.M., Lacasse, Y., Goldstein, R.S., Kerstjens, H.A., Wijkstra, P.J., Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. Respir Med 108 (2014), 329–337.
234. 234 Tiong, L.U., Davies, R., Gibson, P.G., Hensley, M.J., Hepworth, R., Lasserson, T.J., et al. Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst Rev, 2006, Cd001001.
235. 235 Weill, D., Benden, C., Corris, P.A., Dark, J.H., Davis, R.D., Keshavjee, S., et al. A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 34 (2015), 1–15.
236. 236 ISHLT Slide Sets - Overall Lung Transplantation Statistics. International Society for Heart & Lung Transplantation; 2016. Disponible en: https://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry.
237. 237 Wedzicha, J.A., Seemungal, T.A., COPD exacerbations: defining their cause and prevention. Lancet 370 (2007), 786–796.
238. 238 Seemungal, T.A., Donaldson, G.C., Paul, E.A., Bestall, J.C., Jeffries, D.J., Wedzicha, J.A., Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 (1998), 1418–1422.
239. 239 Anthonisen, N.R., Manfreda, J., Warren, C.P., Hershfield, E.S., Harding, G.K., Nelson, N.A., Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987), 196–204.
240. 240 Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Ieven, M., Ortqvist, A., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26 (2005), 1138–1180.
241. 241 White, A.J., Gompertz, S., Stockley, R.A., Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 58 (2003), 73–80.
242. 242 Papi, A., Bellettato, C.M., Braccioni, F., Romagnoli, M., Casolari, P., Caramori, G., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 173 (2006), 1114–1121.
243. 243 Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Pancholi, M., Venge, P., et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 186 (2012), 48–55.
244. 244 Seemungal, T.A., Donaldson, G.C., Bhowmik, A., Jeffries, D.J., Wedzicha, J.A., Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000), 1608–1613.
245. 245 Hurst, J.R., Donaldson, G.C., Quint, J.K., Goldring, J.J., Baghai-Ravary, R., Wedzicha, J.A., Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 179 (2009), 369–374.
246. 246 Wells, J.M., Washko, G.R., Han, M.K., Abbas, N., Nath, H., Mamary, A.J., et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 367 (2012), 913–921.
247. 247 Han, M.K., Kazerooni, E.A., Lynch, D.A., Liu, L.X., Murray, S., Curtis, J.L., et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 261 (2011), 274–282.
248. 248 Kim, V., Han, M.K., Vance, G.B., Make, B.J., Newell, J.D., Hokanson, J.E., et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 140 (2011), 626–633.
249. 249 Burgel, P.R., Nesme-Meyer, P., Chanez, P., Caillaud, D., Carre, P., Perez, T., et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 135 (2009), 975–982.
250. 250 Martinez, F.J., Han, M.K., Flaherty, K., Curtis, J., Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert review of anti-infective therapy 4 (2006), 101–124.
251. 251 Hurst, J.R., Vestbo, J., Anzueto, A., Locantore, N., Mullerova, H., Tal-Singer, R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363 (2010), 1128–1138.
252. 252 Celli, B.R., Thomas, N.E., Anderson, J.A., Ferguson, G.T., Jenkins, C.R., Jones, P.W., et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178 (2008), 332–338.
253. 253 Tashkin, D.P., Celli, B., Decramer, M., Liu, D., Burkhart, D., Cassino, C., et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 31 (2008), 742–750.
254. 254 Hoogendoorn, M., Hoogenveen, R.T., Rutten-van Molken, M.P., Vestbo, J., Feenstra, T.L., Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur Respir J 37 (2011), 508–515.
255. 255 Piquet, J., Chavaillon, J.M., David, P., Martin, F., Blanchon, F., Roche, N., et al. High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J 42 (2013), 946–955.
256. 256 Singanayagam, A., Schembri, S., Chalmers, J.D., Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thorac Soc 10 (2013), 81–89.
257. 257 Garcia-Aymerich, J., Serra Pons, I., Mannino, D.M., Maas, A.K., Miller, D.P., Davis, K.J., Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax 66 (2011), 585–590.
258. 258 National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. NICE Guideline CG012010. Disponible en: https://www.nice.org.uk/guidance/CG101.
259. 259 Celli, B.R., MacNee, W., ATS ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004), 932–946.
260. 260 Turner, M.O., Patel, A., Ginsburg, S., FitzGerald, J.M., Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med 157 (1997), 1736–1744.
261. 261 Barr, R.G., Rowe, B.H., Camargo, C.A. Jr., Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ, 327, 2003, 643.
262. 262 Duffy, N., Walker, P., Diamantea, F., Calverley, P.M., Davies, L., Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 60 (2005), 713–717.
263. 263 Davies, L., Angus, R.M., Calverley, P.M., Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 354 (1999), 456–460.
264. 264 Maltais, F., Ostinelli, J., Bourbeau, J., Tonnel, A.B., Jacquemet, N., Haddon, J., et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 165 (2002), 698–703.
265. 265 Niewoehner, D.E., Erbland, M.L., Deupree, R.H., Collins, D., Gross, N.J., Light, R.W., et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 340 (1999), 1941–1947.
266. 266 Thompson, W.H., Nielson, C.P., Carvalho, P., Charan, N.B., Crowley, J.J., Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 154 (1996), 407–412.
267. 267 Alia, I., de la Cal, M.A., Esteban, A., Abella, A., Ferrer, R., Molina, F.J., et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 171 (2011), 1939–1946.
268. 268 Aaron, S.D., Vandemheen, K.L., Hebert, P., Dales, R., Stiell, I.G., Ahuja, J., et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 348 (2003), 2618–2625.
269. 269 Leuppi, J.D., Schuetz, P., Bingisser, R., Bodmer, M., Briel, M., Drescher, T., et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. Jama 309 (2013), 2223–2231.
270. 270 de Jong, Y.P., Uil, S.M., Grotjohan, H.P., Postma, D.S., Kerstjens, H.A., van den Berg, J.W., Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 132 (2007), 1741–1747.
271. 271 Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Reid, C., Haldar, P., et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 184 (2011), 662–671.
272. 272 Vollenweider, D.J., Jarrett, H., Steurer-Stey, C.A., Garcia-Aymerich, J., Puhan, M.A., Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 12, 2012, Cd010257.
273. 273 Miravitlles, M., Kruesmann, F., Haverstock, D., Perroncel, R., Choudhri, S.H., Arvis, P., Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J 39 (2012), 1354–1360.
274. 274 Stockley, R.A., O'Brien, C., Pye, A., Hill, S.L., Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 117 (2000), 1638–1645.
275. 275 Ram, F.S., Rodriguez-Roisin, R., Granados-Navarrete, A., Garcia-Aymerich, J., Barnes, N.C., Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2006, CD004403.
276. 276 Schuetz, P., Christ-Crain, M., Thomann, R., Falconnier, C., Wolbers, M., Widmer, I., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. Jama 302 (2009), 1059–1066.
277. 277 Schuetz, P., Muller, B., Christ-Crain, M., Stolz, D., Tamm, M., Bouadma, L., et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev, 2012, Cd007498.
278. 278 Nouira, S., Marghli, S., Belghith, M., Besbes, L., Elatrous, S., Abroug, F., Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo- controlled trial. Lancet 358 (2001), 2020–2025.
279. 279 Masterton, R.G., Burley, C.J., Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 18 (2001), 503–512.
280. 280 Adams S, J.M., Luther, M., Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of chronic obstructive pulmonary disease. Chest 117 (2000), 1345–1352.
281. 281 Miravitlles, M., Espinosa, C., Fernandez-Laso, E., Martos, J.A., Maldonado, J.A., Gallego, M., Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 116 (1999), 40–46.
282. 282 Soler, N., Torres, A., Ewig, S., Gonzalez, J., Celis, R., El-Ebiary, M., et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 157 (1998), 1498–1505.
283. 283 Austin, M.A., Wills, K.E., Blizzard, L., Walters, E.H., Wood-Baker, R., Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ, 341, 2010, c5462.
284. 284 Brochard, L., Mancebo, J., Wysocki, M., Lofaso, F., Conti, G., Rauss, A., et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 333 (1995), 817–822.
285. 285 Lightowler, J.V., Wedzicha, J.A., Elliott, M.W., Ram, F.S., Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ, 326, 2003, 185.
286. 286 Meyer, T.J., Hill, N.S., Noninvasive positive pressure ventilation to treat respiratory failure. Ann Intern Med 120 (1994), 760–770.
287. 287 Chandra, D., Stamm, J.A., Taylor, B., Ramos, R.M., Satterwhite, L., Krishnan, J.A., et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med 185 (2012), 152–159.
288. 288 Consensus development conference committee. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation–a consensus conference report. Chest 116 (1999), 521–534.
289. 289 Bott, J., Carroll, M.P., Conway, J.H., Keilty, S.E., Ward, E.M., Brown, A.M., et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet 341 (1993), 1555–1557.
290. 290 Kramer, N., Meyer, T.J., Meharg, J., Cece, R.D., Hill, N.S., Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 151 (1995), 1799–1806.
291. 291 Plant, P.K., Owen, J.L., Elliott, M.W., Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 355 (2000), 1931–1935.
292. 292 Conti, G., Antonelli, M., Navalesi, P., Rocco, M., Bufi, M., Spadetta, G., et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. Intensive Care Med 28 (2002), 1701–1707.
293. 293 Jennings, J.H., Thavarajah, K., Mendez, M.P., Eichenhorn, M., Kvale, P., Yessayan, L., Predischarge bundle for patients with acute exacerbations of COPD to reduce readmissions and ED visits: a randomized controlled trial. Chest 147 (2015), 1227–1234.
294. 294 Singh, G., Zhang, W., Kuo, Y.F., Sharma, G., Association of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD. Chest 149 (2016), 905–915.
295. 295 Ringbaek, T., Green, A., Laursen, L.C., Frausing, E., Brondum, E., Ulrik, C.S., Effect of tele health care on exacerbations and hospital admissions in patients with chronic obstructive pulmonary disease: a randomized clinical trial. Int J Chron Obstruct Pulmon Dis 10 (2015), 1801–1808.
296. 296 Hartl, S., Lopez-Campos, J.L., Pozo-Rodriguez, F., Castro-Acosta, A., Studnicka, M., Kaiser, B., et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J 47 (2016), 113–121.
297. 297 Jordan, R.E., Majothi, S., Heneghan, N.R., Blissett, D.B., Riley, R.D., Sitch, A.J., et al. Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. Health Technol Assess 19 (2015), 1–516.
298. 298 Gavish, R., Levy, A., Dekel, O.K., Karp, E., Maimon, N., The Association Between Hospital Readmission and Pulmonologist Follow-up Visits in Patients With COPD. Chest 148 (2015), 375–381.
299. 299 Oga, T., Tsukino, M., Hajiro, T., Ikeda, A., Nishimura, K., Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 6 (2011), 521–526.
300. 300 Martinez-Garcia, M.A., de la Rosa Carrillo, D., Soler-Cataluna, J.J., Donat-Sanz, Y., Serra, P.C., Lerma, M.A., et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187 (2013), 823–831.
301. 301 Barnes, P.J., Celli, B.R., Systemic manifestations and comorbidities of COPD. Eur Respir J 33 (2009), 1165–1185.
302. 302 Mannino, D.M., Thorn, D., Swensen, A., Holguin, F., Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 32 (2008), 962–969.
303. 303 Sin, D.D., Anthonisen, N.R., Soriano, J.B., Agusti, A.G., Mortality in COPD: Role of comorbidities. Eur Respir J 28 (2006), 1245–1257.
304. 304 Iversen, K.K., Kjaergaard, J., Akkan, D., Kober, L., Torp-Pedersen, C., Hassager, C., et al. The prognostic importance of lung function in patients admitted with heart failure. Eur J Heart Fail 12 (2010), 685–691.
305. 305 Almagro, P., Soriano, J.B., Cabrera, F.J., Boixeda, R., Alonso-Ortiz, M.B., Barreiro, B., et al. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest 145 (2014), 972–980.
306. 306 Miller, J., Edwards, L.D., Agusti, A., Bakke, P., Calverley, P.M., Celli, B., et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 107 (2013), 1376–1384.
307. 307 Campo, G., Napoli, N., Serenelli, C., Tebaldi, M., Ferrari, R., Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. Int J Cardiol 167 (2013), 296–297.
308. 308 Fabbri, L.M., Luppi, F., Beghe, B., Rabe, K.F., Complex chronic comorbidities of COPD. Eur Respir J 31 (2008), 204–212.
309. 309 Bhatt, S.P., Dransfield, M.T., Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 162 (2013), 237–251.
310. 310 Matamis, D., Tsagourias, M., Papathanasiou, A., Sineffaki, H., Lepida, D., Galiatsou, E., et al. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. J Crit Care 29 (2014), 315.e7–315.e14.
311. 311 MacDonald, M.I., Shafuddin, E., King, P.T., Chang, C.L., Bardin, P.G., Hancox, R.J., Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med 4 (2016), 138–148.
312. 312 Lipworth, B., Wedzicha, J., Devereux, G., Vestbo, J., Dransfield, M.T., Beta-blockers in COPD: time for reappraisal. Eur Respir J. 48 (2016), 880–888.
313. 313 Hoiseth, A.D., Neukamm, A., Karlsson, B.D., Omland, T., Brekke, P.H., Soyseth, V., Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 66 (2011), 775–781.
314. 314 Singh, S., Loke, Y.K., Enright, P., Furberg, C.D., Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 68 (2013), 114–116.
315. 315 Wilchesky, M., Ernst, P., Brophy, J.M., Platt, R.W., Suissa, S., Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 142 (2012), 305–311.
316. 316 Salpeter, S.R., Ormiston, T.M., Salpeter, E.E., Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 125 (2004), 2309–2311.
317. 317 Tashkin, D.P., Fabbri, L.M., Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res, 11, 2010, 149.
318. 318 Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003), 449–456.
319. 319 Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003), 74–81.
320. 320 Calverley, P.M., Boonsawat, W., Cseke, Z., Zhong, N., Peterson, S., Olsson, H., Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22 (2003), 912–919.
321. 321 Calverley, P.M., Anderson, J.A., Celli, B., Ferguson, G.T., Jenkins, C., Jones, P.W., et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax 65 (2010), 719–725.
322. 322 Vestbo, J., Anderson, J.A., Brook, R.D., Calverley, P.M., Celli, B.R., Crim, C., et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 387 (2016), 1817–1826.
323. 323 Houben-Wilke, S., Jorres, R.A., Bals, R., Franssen, F.M., Glaser, S., Holle, R., et al. Peripheral Artery Disease and its Clinical Relevance in Patients with COPD in the COSYCONET Study. Am J Respir Crit Care Med, 2016 EPub 17 Aug 2016.
324. 324 Divo, M., Cote, C., de Torres, J.P., Casanova, C., Marin, J.M., Pinto-Plata, V., et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186 (2012), 155–161.
325. 325 Bon, J., Fuhrman, C.R., Weissfeld, J.L., Duncan, S.R., Branch, R.A., Chang, C.C., et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 183 (2011), 885–890.
326. 326 McAllister, D.A., Maclay, J.D., Mills, N.L., Mair, G., Miller, J., Anderson, D., et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176 (2007), 1208–1214.
327. 327 Bolton, C.E., Cannings-John, R., Edwards, P.H., Ionescu, A.A., Evans, W.D., Pettit, R.J., et al. What community measurements can be used to predict bone disease in patients with COPD?. Respir Med 102 (2008), 651–657.
328. 328 Bolton, C.E., Ionescu, A.A., Shiels, K.M., Pettit, R.J., Edwards, P.H., Stone, M.D., et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004), 1286–1293.
329. 329 Jaramillo, J.D., Wilson, C., Stinson, D.S., Lynch, D.A., Bowler, R.P., Lutz, S., et al. Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD Patients at Increased Risk. Ann Am Thorac Soc 12 (2015), 648–656.
330. 330 Jaramillo, J., Wilson, C., Stinson, D., Lynch, D., Bowler, R., Lutz, S., et al. Erratum: reduced bone density and vertebral fractures in smokers. men and COPD patients at increased risk. Ann Am Thorac Soc, 12, 2015, 1112.
331. 331 Ng, T.P., Niti, M., Tan, W.C., Cao, Z., Ong, K.C., Eng, P., Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 167 (2007), 60–67.
332. 332 Eisner, M.D., Blanc, P.D., Yelin, E.H., Katz, P.P., Sanchez, G., Iribarren, C., et al. Influence of anxiety on health outcomes in COPD. Thorax 65 (2010), 229–234.
333. 333 de Torres, J.P., Bastarrika, G., Wisnivesky, J.P., Alcaide, A.B., Campo, A., Seijo, L.M., et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 132 (2007), 1932–1938.
334. 334 Wilson, D.O., Leader, J.K., Fuhrman, C.R., Reilly, J.J., Sciurba, F.C., Weissfeld, J.L., Quantitative computed tomography analysis, airflow obstruction, and lung cancer in the pittsburgh lung screening study. J Thorac Oncol 6 (2011), 1200–1205.
335. 335 Wilson, D.O., Weissfeld, J.L., Balkan, A., Schragin, J.G., Fuhrman, C.R., Fisher, S.N., et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med 178 (2008), 738–744.
336. 336 de-Torres, J.P., Wilson, D.O., Sanchez-Salcedo, P., Weissfeld, J.L., Berto, J., Campo, A., et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med 191 (2015), 285–291.
337. 337 Aberle, D.R., Adams, A.M., Berg, C.D., Black, W.C., Clapp, J.D., Fagerstrom, R.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (2011), 395–409.
338. 338 Infante, M., Cavuto, S., Lutman, F.R., Passera, E., Chiarenza, M., Chiesa, G., et al. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med 191 (2015), 1166–1175.
339. 339 Cebron Lipovec, N., Beijers, R.J., van den Borst, B., Doehner, W., Lainscak, M., Schols, A.M., The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. COPD 13 (2016), 399–406.
340. 340 Martinez, C.H., Okajima, Y., Murray, S., Washko, G.R., Martinez, F.J., Silverman, E.K., et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. Respir Res, 15, 2014, 62.
341. 341 Ingebrigtsen, T.S., Marott, J.L., Vestbo, J., Nordestgaard, B.G., Hallas, J., Lange, P., Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology 20 (2015), 101–107.
342. 342 Patel, I.S., Vlahos, I., Wilkinson, T.M., Lloyd-Owen, S.J., Donaldson, G.C., Wilks, M., et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 (2004), 400–407.
343. 343 Shepard, J.W. Jr., Garrison, M.W., Grither, D.A., Evans, R., Schweitzer, P.K., Relationship of ventricular ectopy to nocturnal oxygen desaturation in patients with chronic obstructive pulmonary disease. Am J Med 78 (1985), 28–34.
344. 344 Bradley, T.D., Rutherford, R., Grossman, R.F., Lue, F., Zamel, N., Moldofsky, H., et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 131 (1985), 835–839.
345. 345 Weitzenblum, E., Krieger, J., Apprill, M., Vallee, E., Ehrhart, M., Ratomaharo, J., et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am Rev Respir Dis 138 (1988), 345–349.